Skip to main content
Clinical Trials/NCT03479255
NCT03479255
Completed
N/A

Smartphone-Enabled Supervised Exercise Therapy for the Treatment of Symptomatic Peripheral Arterial Disease

Emory University1 site in 1 country46 target enrollmentAugust 24, 2018

Overview

Phase
N/A
Intervention
Not specified
Conditions
Peripheral Arterial Disease
Sponsor
Emory University
Enrollment
46
Locations
1
Primary Endpoint
Change in 6-minute walk test (6MWT) distance completed
Status
Completed
Last Updated
last year

Overview

Brief Summary

The study aim is to evaluate the effectiveness of a coached, smartphone-enabled exercise program versus physician directed exercise therapy (usual care).

Detailed Description

Structured exercise therapy is a first line treatment for symptomatic peripheral artery disease, but compliance is poor. Coaching programs may help but requires significant resources. Smartphone programs may increase the efficiency of such efforts. The study aim is to evaluate the effectiveness of a coached, smartphone-enabled exercise program versus physician directed exercise therapy (usual care) in patients at Grady Memorial Hospital's vascular clinic.

Registry
clinicaltrials.gov
Start Date
August 24, 2018
End Date
February 20, 2025
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Amit J. Shah

Assistant Professor

Emory University

Eligibility Criteria

Inclusion Criteria

  • Clinically stable intermittent claudication
  • Able to give informed consent
  • Age 18-89 years
  • And one of the following:
  • ABI \< 0.9 after 10 minutes of rest OR
  • For subjects with an ABI of \>1.3 (non-compressible arteries) a Toe-Brachial Index (TBI) of \< 0.70 must be obtained for subject qualification. If ABI is \> 0.9 to 1.0, a reduction of 20% in ABI must be measured within 1 minute of treadmill testing.

Exclusion Criteria

  • Life-threatening process including:
  • Critical limb ischemia (Rutherford class 4-6)
  • Unstable angina
  • Active malignancy with life expectancy \< 6 months
  • Severe NYHA Class IV heart failure
  • Condition other than PAD that limits walking before claudication onset
  • This includes, but is not limited to:
  • Severe angina or dyspnea
  • Arthritis
  • Muscle weakness/pain

Outcomes

Primary Outcomes

Change in 6-minute walk test (6MWT) distance completed

Time Frame: Immediately before and after the 12-week period

The 6 Minute Walk Test is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity.

Secondary Outcomes

  • Change in claudication onset time during 6MWT(Immediately before and after the 12-week period)
  • Change in Physical Health Composite Score of SF-36(Immediately before and after the 12-week period)
  • Change in ankle-brachial pressure index (ABPI)(Immediately before and after the 12-week period)
  • Mortality(Over the 12-week study period)
  • Change in Walking Impairment Questionnaire (WIQ) score(Immediately before and after the 12-week period)
  • Change in number of steps/week(Immediately before and after the 12-week period)
  • Exercise-Related Injury(Over the 12-week study period)
  • Critical Limb Ischemia(Over the 12-week study period)
  • Other Cardiovascular Outcomes(Over the 12-week study period)

Study Sites (1)

Loading locations...

Similar Trials